A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Ann Oncol
; 28(9): 2241-2247, 2017 Sep 01.
Article
in En
| MEDLINE
| ID: mdl-28911085
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Furans
/
Ketones
/
Lung Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2017
Document type:
Article
Affiliation country:
Japón
Country of publication:
Reino Unido